The crisis around Valeant Pharmaceuticals International deepened, as questions swirled about the tenure of Chief Executive Michael Pearson and the company’s shares fell to their lowest level in 2½ years.
from WSJ.com: US Business http://ift.tt/1HvsfKs
via IFTTT
No comments:
Post a Comment